Zusammenfassung
Die Prognose des Magenkarzinoms ist weiterhin besonders ungünstig. Die Chirurgie kann nur bei einem kleinen Teil der Patienten eine Heilung bzw. ein längerfristiges krankheitsfreies Überleben erzielen, da die meisten Magenkarzinome in weit fortgeschrittenen Tumorstadien diagnostiziert werden. Mehr als 85% aller Patienten mit einem neu diagnostizierten Magenkarzinom sterben an einem irresek-tablen lokalen Tumor und/oder Fernmetastasen. Aus diesem Grund ist die Chemotherapie die Behandlung der Wahl bei fortgeschrittenen Magenkarzinomen entweder alleine oder in Kombination mit Chirurgie und/oder Strahlentherapie. Mit häufiger verwendeten Chemotherapieprotokollen wie FAM [1–15], FAB [16–20], und FAP [21–28] werden objektive Ansprechraten von etwa 30–40% erzielt, jedoch selten komplette Remissionen (<5%). In einer Phase-II-Studie mit der Kombination Etoposid/Adriamycin/Cisplatin (EAP) wurde eine Ansprechrate von 73% einschließlich 21% kompletter Remissionen bei 56 Patienten mit fortgeschrittenem Magenkarzinom erreicht [29]. Der Vergleich von EAP mit anderen Kombinationen (FAM, FAB, FAP), die beim Magenkarzinom häufiger eingesetzt werden, zeigt, daß EAP eine höhere Wirksamkeit haben könnte. In dieser Studie wurde bei 6/12 Patienten mit einem nur lokal fortgeschrittenen Magenkarzinom eine komplette Remission induziert. Darüber hinaus konnte gezeigt werden, daß bei einer durch EAP induzierten objektiven Remission eine radikale Resektion von residuellem Tumor möglich wurde.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Beretta G, Fraschini P, Labianca R, et al (1982) The value of FAM polychemotherapy in advanced gastric carcinoma. Proc Amer Soc Clin Oncol 1: 103 (abstr)
Beretta G, Fraschini P, Labianca R, et al (1986) Weekly 5-Fluorouracil (F) versus combination chemotherapy for advanced gastrointestinal carcinomas. Proc Amer Soc Clin Oncol 5: 94 (abstr)
Biran H, Sulkes A (1984) A possible dose-response relationship in „FAM“ chemotherapy for advanced gastric cancer. Proc Amer Soc Clin Oncol 3:132 (abstr)
Cartei G (1985) 5-Fluorouracil, Adriamycin und Mitomycin C beim Magenkarzinom. In: Nagel GA, Bach F, Bartsch HH (eds) Aktuelle Onkologie. Zuckschwerdt, München Bern Wien, pp 56–64
Douglass HO Jr, Lavin PT, Goudsmit A, et al (1984) An eastern cooperative oncology group evaluation of combinations of Methyl-CCNU, Mitomycin C, Adriamaycin, and 5-Fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2: 1372–1381
Fornasiero A, Cartei G, Daniele O, et al (1984) FAM2 regimen in disseminated gastric cancer. Tumori 70: 77–80
Haas C, Oishi N, McDonald B, et al (1983) Southwest oncology group phase II-III gastric cancer study: 5-Fluorouracil, Adriamycin and Mitomycin C±Vincristine (FAM vs V-FAM) compared to Chlorozotocin (CTZ), M-Amsa, and Dihydroxyanthracenedione (DHAD) with unimpressive differences. Proc Amer Soc Clin Oncol 2: 122 (abstr)
Haim N, Cohen Y, Honigman J, et al (1982) Treatment of advanced gastric carcinoma with 5-Fluorouracil, Adriamycin, and Mitomycin C (FAM). Cancer Chemother Pharmacol 8: 277–280
Haim N, Epelbaum R, Cohen Y, et al (1984) Further studies in the treatment of advanced gastric cancer by 5-Fluorouracil, Adriamycin (Doxorubicin) and Mitomycin C (modified FAM). Cancer 54: 1999–2002
Kim NK (1984) Chemotherapy of advanced gastric carcinoma with 5-Fluorouracil, Adriamyein, Mitomycin (FAM), and 5-Fluorouracil, Adriamycin, Cisplatin (FAP) combinations: Experience in South Korea. In: Ogawa M, Muggia FM, Rozencweig M (eds) Adriamycin, its expanding role in cancer treatment. Excerpta Medica, Amsterdam, pp 137–145
MacDonald JS, Schein PS, Wooley PV, et al (1980) 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) combination-chemotherapy for advanced gastric cancer. Ann Int Med 93: 533–536
Oshima K, Yamada T, Nonaka T, et al (1982) Treatment of advanced G.I. cancer with 5-FU, Adriamycin, and Mitomycin C (FAM). Proc 13th Intern Cancer Congr Seattle, 695 (abstr)
Pannetiere FJ, Haas C, McDonald B, et al (1984) Drug combinations in the treatment of gastric adenocarcinoma: A randomized southwest oncology group study. J Clin Oncol 2: 420–424
The Gastrointestinal Tumor Study Group (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1871–1876
The Gastrointestinal Tumor Study Group (1984) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53: 13–17
Levi JA, Dalley DN, Aroney RS (1979) Improved combination chemotherapy in advanced gastric cancer. Brit Med J 2: 1471–1473
Levi JA, Fox RM, Tattersall MH, et al (1986) Analysis of a prospective randomized comparison of Doxorubicin versus 5-Fluorouracil, Doxorubicin, and BCNU in advanced gastric cancer: Implications for future studies. J Clin Oncol 4: 1348–1355
Lopez M, Di Lauro L, Papaldo P, et al (1986) Treatment of advanced gastric carcinoma with 5-Fluorouracil, Adriamycin, and BCNU. Oncology 43: 288–291
Lopez M, Perno CF, Di Lauro L, et al (1984) 5-Fluorouracil, Adriamycin, BCNU (FAB) combination chemotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 12: 194–197
Schnitzler G, Queißer W, Heim ME, et al (1986) Phase III study of 5-Fu and Carmustine versus 5-Fu, Carmustine, and Doxorubicin in advanced gastric cancer. Cancer Treat Rep 70: 477–479
Cazap EL, Gisselbrecht C, Smith FP, et al (1986) Phase II trials of 5-FU, Doxorubicin, and Cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. Cancer Treat Rep 70: 781–783
Figoli F, Galligioni E, Crivellari D, et al (1986) Cisplatin (DDP) in combination with Adriamycin (A) and Fluorouracil (F) (DAF) in advanced gastric cancer — A phase II study. Proc Amer Soc Clin Oncol 5: 95 (abstr)
Moertel CG, Fleming T, O’Connell MJ, et al (1986) A phase II study of combined 5-Fluorouracil, Doxorubicin, and Cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J Clin Oncol 4: 1053–1057
Moertel CG, Rubin J, O’Connell MJ, et al (1986) A phase II study of combined 5-Fluorouracil, Doxorubicin, and Cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053–1057
Robinson E, Haim N, Epelbaum R, et al (1985) Phase II trials in the treatment of advanced gastric cancer, I — 5-Fluorouracil, Adriamycin and Mitomycin (FAM), II — Cisplatin, Adriamycin and 5-Fluorouracil (DAF). Proc Amer Soc Clin Oncol 4: 77 (abstr)
Rougier P, Droz JP, Amiel JL, et al (1985) Gastric carcinoma: A phase II trial of chemotherapy with association 5-Fluorouracil (5-FU), Adriamycin (ADR) and Cisplatin (DDP) (FAP protocol) in metastasized or inoperable patients. Preliminary results. Cancer Chemother Pharmacol 14 (Suppl): 54–59
Wagener DJT, Yap SH, Wobbes T, et al (1985) Phase II trial of 5-Fluorouracil, Adriamycin, and Cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15: 86–87
Wooley P, Smith F, Estevez R, et al (1981) A phase II trial of 5-Fu, Adriamycin and Cisplatin (FAP) in advanced gastric cancer. Proc Amer Soc Clin Oncol & Amer Assoc Cancer Res 22: 455 (abstr)
Preusser P, Wilke H, Achterrath W, et al (1987) Advanced gastric carcinoma: A phase II study with Etoposide (E), Adriamycin (A), and split course Cisplatin (P) = EAR. Proc Amer Soc Clin Oncol 6: 292 (abstr)
Fujimoto S, Akao T, Itol B, Koshizuka I, Koyano K (1976) A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion therapy and surgery. Cancer 37: 1648
Nishioka B, Ouchi T, Watanabe S, et al (1982) Follow-up study of preoperative oral administration of an antineoplastic agent as an adjuvant chemotherapy in gastric cancer. Gan To Kagaku Ryoho 9: 1427
Stephens FO, Johnson AW, Crea P (1984) Preoperative „basal“ chemotherapy in the management of cancer of the stomach. Med J Aust 140: 143
Jinnai D, Higashi H (1976) Extended radical operation with preoperative chemotherapy for gastric cancer. In: Hirayama T (ed) Cancer in Asia. Univ Park Press, Baltimore, pp 111–119
Klein HO (1985) Preoperative chemotherapy in patients with gastric cancer. Prog Clin Biol Res 201: 283–293
Bonatsos C, Aust J, Meisner D, et al (1985) Preoperative chemotherapy for patients with locally advanced gastric cancer. Proc Amer Soc Clin Oncol 4: 83 (abstr)
Clark JR, Fallon BG, Frei III E (1987) Induction chemotherapy as initial treatment for advanced head and neck cancer: A model for the multidisciplinary treatment of solid tumors. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 175–195
Rosen G, Nirenberg A (1985) Neoadjuvant chemotherapy for osteogenic sarcoma: A five-year follow-up (T-10) and preliminary report of new studies (T-12). In: Wagener DJ, Blijham GH, Smeets JBE, Wils JA (eds) Primary chemotherapy in Cancer Medicine. Liss, New York, pp 39–51
Advani SJ, Saiki TK, Swaroop S, et al (1985) Anterior chemotherapy in esophageal cancer. Cancer 56:1502–1506
Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733
Goldie JH, Coldman AJ (1983) Quantitive model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67: 923–931
Fisher D, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488–1492
Van Putten LM (1985) Optimal timing of adjuvant chemotherapy in mouse models. In: Wagener DJT, Blijham GH, Smeets JBE, Wils JA (eds) Primary chemotherapy in cancer medicine. Liss, New York, pp 15–21
Rubin P, Casarett GW (1968) Clinical Radiation Pathology. Saunders, Philadelphia
Reinhold HS, Buisman GH (1973) Radiosensitivity of capillary endothelium. Br J Radiol 46: 54–57
Meyer HJ, Pichmayr R (1987) Patterns of recurrence to therapeutic strategy in gastric cancer. Scand J Gastroenterol 22: 45–48
Trompke R, Grege A, Keser M (1965) Zum natürlichen Verlauf des Magenkrebses. Bruns’ Beitr Klin Chir 211: 19–36
Moertel CG (1968) The natural history of advanced gastric cancer. Surg Gynec Obstet 126: 1071–1074
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Wilke, H. et al. (1989). Präoperative („neoadjuvante“) Chemotherapie bei lokal fortgeschrittenen Magenkarzinomen. In: Hotz, J., et al. Magenkarzinom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22121-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-662-22121-1_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19001-1
Online ISBN: 978-3-662-22121-1
eBook Packages: Springer Book Archive